Toshinobu Fujiwara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshinobu Fujiwara has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Akihiko Kondo
Kobe University 1-1 Rokkodai , Nada
1 shared publication Akira Fukao
Laboratory of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan
1 shared publication- Chiaki Ogino
Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe 657-8501, Hyogo, Japan
1 shared publication Christian Thoma
Department of Medicine II, University Hospital of Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany
1 shared publicationHiroaki Imataka
Department of Materials Science and Chemistry, Graduate School of Engineering, University of Hyogo, Himeji 671-2280, Japan
1 shared publication- Hiroaki Mieda
Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan
1 shared publication
Latest Publications
- 1 October 2014
- Published by Elsevier in Molecular Cell
- Vol. 56 (1) , 79-89
MicroRNAs Trigger Dissociation of eIF4AI and eIF4AII from Target mRNAs in Humans
- 1 October 2014
- Published by Elsevier in Molecular Cell
- Vol. 56 (1) , 79-89
MicroRNAs Trigger Dissociation of eIF4AI and eIF4AII from Target mRNAs in Humans
- Open Access
- 24 June 2013
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 11 (1) , 19
Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Background: Small interfering RNA (siRNA) has attracted attention in the field of nucleic acid medicine as a RNA interference (RNAi) application that leads to gene silencing due to specific messenger RNA (mRNA) destruction. However, since siRNA is unstable in blood and unable to cross the cell membrane, encapsulation of siRNA into a carrier is required. Results: In this study, we used a carrier that combined ZHER2-displaying bio-nanocapsule (derived from hepatitis B virus surface antigen) and liposomes in a complex in order to investigate the feasibility of effective and target-cell-specific RNAi applications. As a result, by observing RNAi only in HER2-expressing breast cancer cells, using our proposed methodology, we successfully demonstrated target-cell-specific delivery and effective function expression of siRNA. Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
- 24 June 2013
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 11 (1) , 19
Open AccessTargeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Background: Small interfering RNA (siRNA) has attracted attention in the field of nucleic acid medicine as a RNA interference (RNAi) application that leads to gene silencing due to specific messenger RNA (mRNA) destruction. However, since siRNA is unstable in blood and unable to cross the cell membrane, encapsulation of siRNA into a carrier is required. Results: In this study, we used a carrier that combined ZHER2-displaying bio-nanocapsule (derived from hepatitis B virus surface antigen) and liposomes in a complex in order to investigate the feasibility of effective and target-cell-specific RNAi applications. As a result, by observing RNAi only in HER2-expressing breast cancer cells, using our proposed methodology, we successfully demonstrated target-cell-specific delivery and effective function expression of siRNA. Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.